Midweek Market Podcast – August 25

Geopolitical risks and virus developments have remained in focus and add to the cautious backdrop. Trading has been very muted, with investors clearly holding back ahead of the Jackson Hole weekend.



The Market Week – August Week 4

Jackson Hole remains the main focus for markets this week, even if expectations for an early tapering announcement have faded amid concern that the rapidly spreading Delta variant will at the very least dampen the recovery. This weighed on the Greenback turning it to a 1-week low.

Treasuries posted modest losses as Wall Street rallied. Bonds were also heavy amid the weight of the $183 bln in supply. A stellar 2-year auction helped the front end rebound and gain some ground.

Major stock indexes are narrowly mixed. Key equity indices in both the US and Europe stalled at month highs with the exception of the USA100 and USA500.  The USA30 holds near 35,500, the UK100 is stuck at the 7,100 area, while the GER30 is shy of 16,000.

USA100 and USA500 hit new highs as well, with the former breaking the 15,000 level. The rally was supported by solid earnings once again but also as tech shares have outperformed, as shares of beaten down China stocks recover on hopes for more clarity from Chinese regulators.

The full approval of Pfizer’s Covid vaccine on Monday has helped stocks as well, in hopes vaccination rates in the US will now rise.

In the currency market, the EURUSD peaked at 1.1765, as dollar weakens after the market priced in a push back for QE tapering. The USDJPY has continued to ply a narrow range in the mid-to-upper 109.00 range. Cable flirts with 1.3750, retaining a neutral-to-bullish outlook, even though incoming data are showing a moderation in the pace of economic growth.

Safe haven gold fell in tandem with the broad increase in risk appetite, with XAUUSD pulling back to $1,791 from $1,809.50.

USOil bounced quite sharply to $67 highs, up from 4-month lows of $61.46 as the hopes for a demand recovery helped sentiment, following the full FDA approval of Pfizer’s vaccine.

Click here to access our Economic Calendar

Andria Pichidi

Market Analyst

Disclaimer: This material is provided as a general marketing communication for information purposes only and does not constitute an independent investment research. Nothing in this communication contains, or should be considered as containing, an investment advice or an investment recommendation or a solicitation for the purpose of buying or selling of any financial instrument. All information provided is gathered from reputable sources and any information containing an indication of past performance is not a guarantee or reliable indicator of future performance. Users acknowledge that any investment in Leveraged Products is characterized by a certain degree of uncertainty and that any investment of this nature involves a high level of risk for which the users are solely responsible and liable. We assume no liability for any loss arising from any investment made based on the information provided in this communication. This communication must not be reproduced or further distributed without our prior written permission.